Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- City Therapeutics Announces Pricing of Upsized Initial Public OfferingCompanies: Jefferies Financial GroupCity Therapeutics Announces Pricing of Upsized Initial Public Offering
- CYCJET UV Laser Coding for Flexible Packaging ComplianceChina released GB 7718-2025 on March 16, 2025, with implementation set for March 16, 2027. As the food and pharmaceutical packaging industries face growing demands for marking clarity and traceability, CYCJET, brand of Shanghai Yuchang Industrial Co., Ltd., has launched the LU5T mini UV laser printer to deliver high-contrast coding on transparent films, aluminum foil, and colored composite films, while supporting production line integration.
- The Rosen Law Firm PAUNICYCIVE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
- Estrella Immunopharma, Inc.Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion PhasePatient received two infusions three weeks apart at the recommended Phase II dose; no treatment-related serious adverse events observed through the first month of follow-up EMERYVILLE, Calif., October 15, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage b
- Symrise Expands Global Production Platform for Sustainable Musk Fragrance IngredientInvestment in world-scale capacity expansion in India for Globalide® to strengthen global supply Sustainable macrocyclic musk fragrance ingredient supports customers in developing future-ready fragrance formulations Globalide® strengthens portfolio of differentiated specialties and supports ONE Symrise strategy HOLZMINDEN, GERMANY - October 15, 2026 - Symrise is investing in an additional production capacity for Globalide® in India, expanding its global footprint for this strategic fragrance ingredient. The company is thus strengthening its ability to supply a sustainable macrocyclic musk fragrance ingredient and is moving closer to high-growth customer markets. At the same time, Symrise is expanding its Aroma Molecules business in an attractive product segment. The investment supports the ONE Symrise strategy through targeted capital allocation, resilient value creation and profitable growth driven by differentiated ingredients. “The investment in our Globalide® production footprint underlines our ambition to strengthen strategic product areas that create tangible value for our customers. With this step we are advancing our Scent & Care portfolio. Also, we are generating additional momentum for Symrise’s growth in line with our ONE Symrise strategy,” says Michael Friede, President Scent & Care at Symrise. Globalide® supports sustainable fragrance concepts In the fast-growing global fragrance ingredients market, ingredients that combine strong olfactory performance with versatility across applications and modern fragrance creations continue to gain importance. To deliver on this demand, Symrise is investing in additional world-scale production capacity for Globalide® in India. The biodegradable macrocyclic musk ingredient adds long-lasting, elegant notes to fragrances and supports customers in developing more sustainable fragrance formulations. “With the additional production capacity in India, we are moving closer to the fast-growing markets in Asia while adding another pillar to our long-term global manufacturing footprint,” says Dr Keke Hiller, Global President Aroma Molecules at Symrise. “Globalide® combines high fragrance quality with a contemporary profile. Drawing on our product and technology expertise, we help customers develop attractive, future-ready products for consumers." Strengthening global supply through targeted investment By expanding its production footprint, Symrise is further strengthening its position in the market for specialty fragrance ingredients. The additional capacity increases flexibility across the global supply network and provides the foundation for meeting growing demand for Globalide® over the long term. Customers benefit from reliable access to an ingredient that combines high-quality fragrance performance with broad formulation versatility. About Symrise Symrise is a global supplier of flavors and fragrances, cosmetic base and active ingredients, and functional ingredients. Its customers include manufacturers of perfume, cosmetics, food, and beverages, as well as the pharmaceutical industry and producers of dietary supplements and pet food. With sales of around EUR 4.9 billion in the 2025 financial year, the company is one of the world’s leading providers. Headquartered in Holzminden, Germany, the Group has more than 100 sites in Europe, Africa and the Middle East, Asia, North America, and Latin America. Together with its customers, Symrise develops new ideas and market-ready concepts for products that have become an indispensable part of everyday life. Economic success and corporate responsibility are inextricably linked. Symrise - always inspiring more... www.symrise.com Media contact: Christina Witter Phone: +49 55 31 90-2182 E-mail: [email protected] Social media: linkedin.com/company/Symrise youtube.com/agsymrise xing.com/companies/symrise instagram.com/symriseag instagram.com/finefragrancestories_bySymrise instagram.com/symrise.ci
- Kaplan Fox & Kilsheimer LLPKaplan Fox Advises Investors of Unicycive Therapeutics, Inc. (UNCY) of an Upcoming Securities Class Action Deadline on November 2, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us. You may...
- AntechNew JAVMA Study Validates Accuplex™ by Antech™ as a Robust Option for Tick-Borne Disease Screening in DogsPeer-reviewed research finds Accuplex™ demonstrated significantly higher sensitivity for Ehrlichias spp. antibody detection compared to the SNAP® 4Dx® Plus test. LOVELAND, Colo., October 15, 2026--Antech, a global leader in veterinary diagnostics, today announced the publication of a new study in the J
- Global Biomarker-Driven Drug Development Market - Strategic Insights and Forecasts, 2026-2031 | Precision Medicine and Multi-Omics Drive 10.2% CAGR to USD 35.9 BillionBoost ROI through pharma-diagnostic collaborations, AI-driven analytics, multi-omics investment, and co-developed companion diagnostics and targeted therapies.
- Eisai Inc.Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026Findings from the Phase 3 LITESPARK-011 and LITESPARK-012 studies reflect continued research into LENVIMA® (lenvatinib)-based combination regimens for patients with advanced renal cell carcinoma Exploratory biomarker analysis from the Phase 3 LEAP-001 study adds to translational insights...
- BetterLife Pharma Inc.BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical OperationsBetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced that Sheila Leitzinger has joined the Company as Head of Clinical Operations.In this role, Ms. Leitzinger will lead clinical trial planning and execution for the initial healthy volunteer study of BETR-001, the Company's lead candidate, before the...
- ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grantOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that it has received new decisions to grant for patent applications in South Korea, the Philippines, New Zealand and Mexico, further strengthening its extensive patent portfolio for vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for psychiatric and neurodevelopmental disorders.
- Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic EsophagitisEupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target.